Biond Biologics
Immunotherapies for Cancer and Auto-immune Diseases
Startup C Health Tech & Life Sciences Est. 2016
🌐 WebsiteLinkedIn
Total Raised
$37M
C
Last Round
$15M
3 rounds
Investors
6
6 public
Team
8
11-50 employees
Confidence
97/100
News
9
articles
Patents
1
About
Biond Biologics is a biotechnology company developing immunotherapies and an intracellular drug delivery platform for the treatment of cancer patients. The company uses biologics targeting novel immune evasion mechanisms, discovered through in-house research utilizing real-world patient and tumor samples. Biond Biologics is developing an intracellular delivery platform for biologics (e.g., antibodies or enzymes) inside cells, allowing the company to drug intracellular targets currently considered "undruggable."
Classification
Sector
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Core Technology
BiologicalsCells
Target Customer
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business Model
B2B
Tags
pharmaceuticalsimmunologydrug-discoveryoncologyautoimmune-diseasesbiopharmaceuticalcancerpharma-companiesimmunotherapy
Funding & Events
Nov 2021
C Round $15M
Deep Insight (Lead), Heritage Group, Harel Insurance & Finance
Jan 2019
B Round $17M
Harel Insurance & Finance (Lead), Celgene Corporation(Japan), SBI JI Innovation Fund, Israel Biotech Fund
A Round $5M
News (9)
Oct 8, 2025 · www.prnewswire.com
growth-positive
/PRNewswire/ -- Biond Biologics Ltd. ("Biond" or the "Company"), a private, clinical-stage biopharmaceutical company developing novel immunotherapies for...
Product StagePartners
May 23, 2022 · www.prnewswire.com
growth-positive
Biond Biologics Announces First Patients Dosed with BND-22 (SAR444881) Combinations in Phase 1 Clinical Trial
PartnersInvestment
Nov 3, 2021 · www.prnewswire.com
growth-positive
Biond Biologics Announces Closing of $15 Million Series C Financing
Investment
Apr 26, 2021 · www.prnewswire.com
growth-positive
Biond Biologics Announces First Patient Dosed in Phase 1 Clinical Trial of BND-22, a Novel Immune Checkpoint Inhibitor Targeting the ILT2 Receptor
CustomersPartners
Jan 12, 2021 · www.prnewswire.com
growth-positive
Biond Biologics and Sanofi Enter into Global Licensing Agreement for BND-22, a Novel Immune Checkpoint Inhibitor Targeting the ILT2 Receptor
Partners
Jun 1, 2020 · www.globenewswire.com
growth-positive
Biond Biologics Appoints Jerome Zeldis, M.D., Ph.D., Former Chief Medical Officer of Celgene, to Board of Directors and Provides Corporate Update
Management Changes
Nov 25, 2019 · www.globenewswire.com
growth-positive
Biond Biologics Appoints Immunotherapy Pioneer Alan Korman Ph.D. to Scientific Advisory Board
Management Changes
Jan 8, 2019 · en.globes.co.il
growth-positive
Israeli co Biond Biologics raises $17m
Investment
May 31, 2016 · en.globes.co.il
growth-positive
Pfizer buys rights to BioRap autoimmune drug
PartnersInvestment
Details
Product Stage
Clinical Trial
Employees
11-50
Exact Count
36
Founded
2016
Registrar
515445823
Crunchbase
biond-biologics
Locations
Misgav, Israel
Links
Website
www.biondbio.com
LinkedIn
Profile
Admin
Last Update
Sep 21, 2024
Verified by
Yanina Wainscheinker
Claimed
Yes
Missing
video or image, markets
Team (8)
Tehila Ben Moshe
Co-founder, Chairperson & CEO
Founder
Ori Shilo
Co-founder & CFO
Founder
Yair Sapir
COO
Avidor Shulman
CTO
Itay Friedman
VP Clinical Development
Ilana Mandel
VP R&D
Sharon Hashmueli
VP Regulatory Affairs & CMC
Tal Sines
Director of Business Development
Internal
Created by
Jenny Sotnik-Talisman (genys30@yahoo.com)
Created
2017-02-26T00:00:00.000Z
Last editor
Yanina Wainscheinker (yanina.wainscheinker@sncentral.org)
Finder · Biond Biologics · 2026